Treatment of Hepatocellular Carcinoma With Lenvatinib

G&H What is the mechanism of action of lenvatinib? K-HH Lenvatinib (Lenvima, Eisai) is a tyrosine kinase inhibitor selectively targeting vascular endothelial growth factor receptor […]

Gastro-Hep News

US Food and Drug Administration Approves Lenvatinib for Hepatocellular Carcinoma On August 16, 2018, the US Food and Drug Administration (FDA) approved the kinase inhibitor lenvatinib […]